Rapid Assembly and Screening of Multivalent Immune Cell-Redirecting Therapies for Leukemia.

ABSTRACT: Therapies that bind with immune cells and redirect their cytotoxic activity toward diseased cells represent a promising and versatile approach to immunotherapy with applications in cancer, lupus, and other diseases; traditional methods for discovering these therapies, however, are often time-intensive and lack the throughput of related target-based discovery approaches. Inspired by the observation that the cytokine, IL-12, can enhance antileukemic activity of the clinically approved T cell redirecting therapy, blinatumomab, here we describe the structure and assembly of a chimeric immune cell-redirecting agent which redirects the lytic activity of primary human T cells toward leukemic B cells and simultaneously cotargets the delivery of T cell-stimulating IL-12. We further describe a novel

SUBMITTER: Do P 

PROVIDER: S-EPMC8496977 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature